Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of Brodalumab in RA
NCT00771030Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2008
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of brodalumab in rheumatoid arthritis (RA) (7 arms), sponsored by Amgen. Primary endpoints: Number of Participants With Treatment-emergent Adverse Events at Week 19, Number of Participants With Clinically Significant Changes in Safety Laboratory Tests at Day 127 and 2 more. Started Oct 2008; status: completed.
02
Drugs
brodalumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00771030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00771030.